On June 1, Smoore International rose 3.96% in regular trading, trading at HK$9.52 per share, with trading volume of HK$15.95 million. The stock showed signs of stabilization after a multi-day correction following a strong rally driven by U.S. FDA regulatory developments.
On the news front, the U.S. FDA previously approved non-tobacco flavored e-cigarettes through the PMTA review process for the first time, propelling Smoore International to accumulate gains exceeding 20% in May. The stock subsequently entered a sustained pullback from May 14, with trading volume shrinking considerably as market participants adopted a wait-and-see stance. After brief stabilization attempts and renewed weakness in late May, the current session marks a more definitive rebound attempt.
Institutional analysts remain constructive on Smoore International's medium-to-long-term outlook, noting that the company's underage user identification technology was a key consideration in the FDA approval process. Core client products and proprietary brands are expected to accelerate through the regulatory pipeline, positioning the company as a direct beneficiary of compliant market recovery.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments